2023 annual financial data
Karyopharm Therapeutics 2023 Operating margin
Direct answer
Operating margin was -88.71%.
Operating income was -129,540,000 USD and net income was -143,099,000 USD.
Operating cash flow was -92,723,000 USD.
Get free Karyopharm Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 146,033,000 USD
- Operating income
- -129,540,000 USD
- Net income
- -143,099,000 USD
- Operating cash flow
- -92,723,000 USD